PUBLIC COMPANY
save$ALKSAlkermes plc.
$ALKS46.53-1.06%Dublin 4, IEupdated 13h ago
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
3
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 11Phase 31Marketed2Unknown
Marketed
(olanzapine + samidorphan l-malate)
Bipolar Disorder (Manic Depression)
Phase 3alixorexton
Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Phase 1valiloxybate ER
Narcolepsy
drugLYBALVI
1 INDICATIONS AND USAGE LYBALVI is indicated for the trea…
D2-like dopamine receptor5-hydroxytryptamine receptor 2C
drugVIVITROL
1 INDICATIONS AND USAGE Treatment with VIVITROL should be…
Opioid receptors; mu/kappa/delta
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →🐶 Hiring Signal
News
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 1mo ago
- STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and moreNovo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicinesstat · 1mo ago
- STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trialThe drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.stat · 1mo ago
- With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…fiercebiotech · 1mo ago
- ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing itAs the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.fiercebiotech · 2mo ago
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 3mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that